Cargando…

Clinical assessment of immune-related adverse events

Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosa, Aaron, Lopez Cadena, Esther, Simon Olive, Cristina, Karachaliou, Niki, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882039/ https://www.ncbi.nlm.nih.gov/pubmed/29623110 http://dx.doi.org/10.1177/1758835918764628

Ejemplares similares

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges
por: Karachaliou, Niki, et al.
Publicado: (2018)

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2018)

Rhomboids and regulation of receptor tyrosine kinase ligands shedding
por: Karachaliou, Niki, et al.
Publicado: (2018)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou, Niki, et al.
Publicado: (2014)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy
por: Rosell, Rafael, et al.
Publicado: (2019)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy
por: Teixidó, Cristina, et al.
Publicado: (2015)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2020)

Immune-Related Adverse Events: Pneumonitis
por: Zhong, Linda, et al.
Publicado: (2020)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Activation of viral defense signaling in cancer
por: Gonzalez-Cao, Maria, et al.
Publicado: (2018)

Human endogenous retroviruses and cancer
por: Gonzalez-Cao, María, et al.
Publicado: (2016)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

Advances in immunotherapy for treatment of lung cancer
por: Bustamante Alvarez, Jean G., et al.
Publicado: (2015)

Gastrointestinal disorders as immune-related adverse events
por: Balducci, Daniele, et al.
Publicado: (2021)

Vasospastic Angina: An Immune-related Adverse Event
por: Kumamoto, Taku, et al.
Publicado: (2021)

Immune-Related Adverse Events of the Gastrointestinal System
por: Nicolaides, Steven, et al.
Publicado: (2023)

The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
por: Hashimoto, Hiroki, et al.
Publicado: (2021)

Care Step Pathway Tools for Immune-Related Adverse Event Assessment and Management
Publicado: (2019)

Tumor immune microenvironment characterization and response to anti-PD-1 therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Microbiome transplantation and modulation of immune related adverse events
por: Smibert, Olivia C., et al.
Publicado: (2019)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Immune-related adverse events: A bibliometric analysis
por: Jiang, Shi-Tao, et al.
Publicado: (2022)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
por: Chieng, Jenny Hui Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4e14qqbpdd2m9ggg1c6sm6328i